Market Cap: $6.13B
LI
Ligand Pharmaceuticals Incorporated
LGND
NASDAQ (NASDAQ Global Market)USD
Market Cap: $6.13B
Ligand Pharmaceuticals (Ticker: LGND) secures $625 million through a strategic capital raise, reflecting a sophisticated approach to financing that aligns with its growth ambitions. The recent issuanc…
Ligand Pharmaceuticals (Ticker: LGND) makes significant strides in aligning leadership interests with shareholder confidence. Recent insider transactions signal positive sentiments about the company's…
Ligand Pharmaceuticals sees significant advancements in its royalty portfolio following the FDA's full approval of FILSPARI, a treatment developed by its partner Travere Therapeutics for focal segment…
Ligand Pharmaceuticals: Insider Confidence Signals Strategic Momentum In a noteworthy development for Ligand Pharmaceuticals, board member John L. LaMattina recently exercised stock options, as reveal…
Ligand Pharmaceuticals Gains Analyst Attention Amid Unique Positioning in Pharma Sector Ligand Pharmaceuticals Inc. (NASDAQ: LGND) captures significant attention as Bank of America (BofA) initiates co…
Bank of America Elevates Ligand Pharmaceuticals’ Profile with New Buy Rating In a strategic move that could bolster its market positioning, Bank of America (BofA) begins coverage of Ligand Pharmaceuti…
Ligand Pharmaceuticals Reports Impressive Quarterly Growth Driven by Strategic Innovations Ligand Pharmaceuticals showcases significant growth in its most recent quarterly earnings report, revealing a…
Ligand Pharmaceuticals: A Leader in Pharmaceutical Innovation Ligand Pharmaceuticals showcases a remarkable trajectory in the biotechnology sector, marked by its impressive annualized return of 26.12%…
Insider Activity Signals Confidence in Ligand Pharmaceuticals' Future Recent insider activity at Ligand Pharmaceuticals (NASDAQ:LGND) has drawn attention, particularly the substantial exercise of stoc…
Insider Activity at Ligand Pharmaceuticals Signals Confidence in Future Prospects Ligand Pharmaceuticals, a prominent player in the biopharmaceutical industry, experiences noteworthy insider activity…
Changing Sentiment in Ligand Pharmaceuticals: A Shift in Short Interest Recent reports indicate that Ligand Pharmaceuticals Inc. experiences a notable reduction in short interest, marking a 7.23% decl…
Emerging Trends in Biotechnology and Ligand Pharmaceuticals' Role Ligand Pharmaceuticals, a key player in the biotechnology sector, continues to navigate the complex landscape of drug development and…
Strategic Partnerships Drive Ligand Pharmaceuticals’ Growth Ahead of Earnings Announcement Ligand Pharmaceuticals is on the cusp of revealing its quarterly earnings on November 6, 2025, and the antici…
Ligand Pharmaceuticals Prepares for Upcoming Earnings Release Amid Strategic Growth Initiatives Ligand Pharmaceuticals is poised to release its quarterly earnings report on November 6, 2025, marking a…
Axsome Therapeutics Gears Up for Critical Earnings Report Amidst Competitive Biotech Landscape Axsome Therapeutics, a key player in the biotech industry, prepares to release its quarterly earnings rep…
Ligand Pharmaceuticals Faces Mixed Analyst Sentiment Amidst Growth Opportunities Ligand Pharmaceuticals is currently navigating a complex landscape, as recent analyses from four different analysts pre…
Pelthos Therapeutics Launches Zelsuvmi: A New Hope for Molluscum Contagiosum Treatment Pelthos Therapeutics Inc. officially launches Zelsuvmi (berdazimer) topical gel 10.3% to address molluscum contag…
Revolutionizing Drug Discovery: The Launch of SAIR by SandboxAQ In a groundbreaking move for the pharmaceutical industry, SandboxAQ has recently unveiled the SAIR (Structurally Augmented IC50 Reposito…
### Transforming Drug Discovery Through AI: The Launch of SAIR On June 18, 2025, SandboxAQ, a leading AI-driven company based in Palo Alto, California, unveils the SAIR (Structurally Augmented IC50 Re…
Ligand Pharmaceuticals Prepares for Year-End Financial Results and Business Update Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) is set to unveil its fourth quarter and full year 2024 financial r…
Ligand Pharmaceuticals Prepares for Oppenheimer Conference Presentation Ligand Pharmaceuticals Incorporated is set to showcase its strategic vision at the upcoming Oppenheimer 35th Annual Healthcare L…
Odyssey Therapeutics Welcomes New CFO to Drive Financial Strategy Odyssey Therapeutics, a clinical-stage biopharmaceutical company specializing in autoimmune and inflammatory diseases, appoints Jason…
Truvian Health Strengthens Board with Appointment of Dr. Tina S. Nova Truvian Health, a company dedicated to transforming blood diagnostics, recently announces the addition of Dr. Tina S. Nova to its…
Ligand Pharmaceuticals Sees Robust Growth Amid Product Launches Ligand Pharmaceuticals Incorporated reports impressive financial results for the third quarter of 2024, underscoring a transformative pe…